Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla's Advair generic hits Europe; eyes Breo version?

This article was originally published in Scrip

Executive Summary

Cipla has launched a "cost-efficient" generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), in Germany and Sweden.

You may also be interested in...



Christmas Cheer For Cipla’s Seretide Equivalent In The UK

Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.

Christmas Cheer For Cipla’s Seretide Equivalent In The UK

Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.

India-China Tango: Can Gland Sustain Listing Luster?

Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel